Company intelligence / Profile preview
Molecular Partners AG
Schlieren, Zürich, Switzerlandmolecularpartners.com ↗
- Ownership
- Public · MOLN
- Employees
- ~152
- Development stage
- Other
01
Overview
Molecular Partners is developing DARPin therapeutics with applications in oncology, immuno-oncology, ophthalmology, and infectious diseases. Their lead candidates include MP0712 (DLL3-Radio-DARPin Therapy) for SCLC and neuroendocrine tumors, MP0274 (targeting Her2) in Phase 1, and MP0310 (FAP x 4-1BB) in Phase 1 in collaboration with Amgen.
- Therapeutic areas
- OphthalmologyOncologyInfectious Diseases
- Modalities
- DARPin therapeuticsRadio-DARPin Therapy (RDT)Switch-DARPin Platform
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $123.2M
- Total revenue
- $0
- Enterprise value
- $56.3M
Beyond the preview
Go deeper on Molecular Partners AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Molecular Partners AG.